Viveve Medical, Inc. (NASDAQ:VIVE) produced a 18.46% rally since recording the worst price of $0.35. Thanks to the latest 6.36% increase, it now trades at $0.41. Throughout the trading on 7/11/2019, the share price floated between $0.387 and $0.47. This company shares are 665.85% off its target price of $3.14 and the current market capitalization stands at $19.53M. The recent change has given its price a -14.88% deficit over SMA 50 and -88.82% deficit over its 52-week high. The stock witnessed -14.99% declines, -27.96% declines and -67.86% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VIVE’s volatility during a week at 11.46% and during a month it has been found around 12.1%.Viveve Medical, Inc. (VIVE) Top Holders
Institutional investors currently hold around $11 million or 64.3% in VIVE stock. Look at its top three institutional owners: Nantahala Capital Management, Llc owns $2.57 million in Viveve Medical, Inc., which represents roughly 13.14% of the company’s market cap and approximately 23.34% of the institutional ownership. Similar statistics are true for the second largest owner, Rtw Investments, Lp, which owns 4,480,565 shares of the stock are valued at $1.75 million. The third largest holder is Stonepine Capital Management, Llc, which currently holds $1.33 million worth of this stock and that ownership represents nearly 6.79% of its market capitalization.
At the end of March reporting period, 9 institutional holders increased their position in Viveve Medical, Inc. (NASDAQ:VIVE) by some 688,795 shares, 21 decreased positions by 1,175,610 and 14 held positions by 25,894,056. That puts total institutional holdings at 27,758,461 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 82,124 shares while 12 institutional investors sold out their entire positions totaling 628,750 shares.Viveve Medical, Inc. (NASDAQ:VIVE) Insider Trades
Multiple company employees have indulged in significant insider trading. Viveve Medical, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Durbin Scott has acquired 5,000 shares of Viveve Medical, Inc. (VIVE) in the trading session dated Aug. 23, 2017. These shares are worth $26,250 and were traded at $5.25 each. The SEC filing shows that Stonepine Capital Management, performed a purchase of 1,250,000 shares. The Director, 10% Owner added these shares by way of transaction on Mar. 17, 2017. The company’s shares were assimilated at $4 per share worth to an investment of some $5,000,000 to the account of Stonepine Capital Management,.
Director, JANNEY DANIEL, purchased 500,000 common shares of Viveve Medical, Inc. (VIVE) in the open market. In a transaction dated Mar. 17, 2017, the shares were bought at an average price of $4, giving away a sum of $2,000,000. After this purchase, 1,385,009 common shares of VIVE are directly owned by the insider, with total stake valued at $567,854.
In the transaction dated Mar. 17, 2017, a great number of shares acquired came courtesy the CEO; Scheller Patricia added a total of 12,500 shares at an average price of $4, amounting to approximately $50,000. The insider now directly owns 45,164 shares worth $18,517.
Several analysts have released their opinion on Viveve Medical, Inc. (NASDAQ:VIVE), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].